Haleon/$HLN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Haleon

Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.

Ticker

$HLN

Primary listing

NYSE

Industry

Pharmaceuticals

Employees

24,561

ISIN

US4055521003

Haleon Metrics

BasicAdvanced
$46B
48.06
$0.22
0.23
$0.18
2.40%

What the Analysts think about Haleon

Analyst ratings (Buy, Hold, Sell) for Haleon stock.

Bulls say / Bears say

Haleon forecasts high single-digit percentage growth in profits from 2026, driven by strong demand in key markets and expected supply chain cost reductions. (reuters.com)
The company reported a 3.5% organic revenue growth in Q1 2025, surpassing analysts' expectations of 3.2%, primarily due to increased demand for its oral health products. (reuters.com)
Haleon has allocated £500 million for share buybacks in the current year, indicating confidence in its financial position and commitment to returning value to shareholders. (reuters.com)
GSK reduced its stake in Haleon to approximately 7.4% by selling shares worth around $1.08 billion, potentially signaling a lack of confidence from a major shareholder. (benzinga.com)
Haleon's P/E ratio of 26.87 is higher than the market average of 23.58, suggesting the stock may be overvalued compared to its earnings. (marketbeat.com)
The company reported a 2.3% decline in first-quarter revenue, attributed to a weaker flu season impacting demand for its cold and cough medicines. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 29 Jun 2025.

Haleon Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Haleon Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $HLN

Sign up or log in to buy
Capital at risk
Market openADR

Upcoming events

No upcoming events
FAQs